We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 2

1.
Fig 1.

Fig 1. From: Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study.

Overall survival and progression-free survival Kaplan-Meier plots for the 46 patients in the study sample.

Bradley J. Monk, et al. J Clin Oncol. 2009 March 1;27(7):1069-1074.
2.
Fig 2.

Fig 2. From: Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study.

Nonrandomized comparison of progression-free survival (PFS) for studies listed in Table 1 and the PFS from Gynecologic Oncology Group Protocol 227-C (current study) with bevacizumab (light yellow). PF, progression free.

Bradley J. Monk, et al. J Clin Oncol. 2009 March 1;27(7):1069-1074.

Supplemental Content

Recent activity

Your browsing activity is temporarily unavailable.

Write to the Help Desk